<DOC>
	<DOCNO>NCT00237458</DOCNO>
	<brief_summary>This trial follow-on trial preceeding open-label trial include patient chronic refractory neuropathic pain . It conduct one site United Kingdom patient enrollment complete . The patient successfully complete mentioned trial , investigator 's opinion , would benefit long-term administration Lacosamide . After 1-week run-in phase patient uptitrated optimal dose continue maintenance phase . Different pain quality assess patient 's diary .</brief_summary>
	<brief_title>An Open-label Continuation Trial Assess Continued Efficacy Safety Ascending Doses Lacosamide Subjects With Chronic Refractory Neuropathic Pain</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Subject inform give ample time opportunity think her/his participation extension trial give her/his write informed consent Subject meet inclusion criterion define SP611 trial SPM927 time enrollment trial SP611 Subject successfully complete trial SP611 , investigator 's opinion , would benefit longterm administration SPM927 Subject willing able comply trial requirement , include ability complete trial questionnaire Subject previously participate trial Subject participate another trial investigational drug within last 3 month ( exclude trial SP611 ) currently participate another trial investigational drug Subject prior therapy Nonsteroidal Antiinflammatory Drug ( NSAID ) Antiepileptic Drug ( AED ) within 28 day prior Eligibility Visit Subject evidence history significant Cardiovascular Disease within 12 month prior Eligibility Visit Subject laboratory value , outside normal range judge Investigator clinically significant Subject abnormal Renal Hepatic function Subject history Malignancies exception subject document diseasefree interval 5 year Subject history chronic alcohol drug abuse within last 12 month Subject medical psychiatric condition , opinion Investigator , could jeopardize compromise subject 's ability participate continuation trial Subject know history severe Anaphylactic Reaction and/or serious life threaten Blood Dyscrasias</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>